KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Times Interest Earned (2017 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Times Interest Earned for 17 consecutive years, with $49.84 as the latest value for Q1 2026.

  • For Q1 2026, Times Interest Earned fell 26.72% year-over-year to $49.84; the TTM value through Mar 2026 reached $75.61, down 5.66%, while the annual FY2025 figure was $81.69, 12.99% up from the prior year.
  • Times Interest Earned hit $49.84 in Q1 2026 for Regeneron Pharmaceuticals, down from $72.12 in the prior quarter.
  • Across five years, Times Interest Earned topped out at $299.86 in Q2 2025 and bottomed at $46.67 in Q1 2024.
  • Average Times Interest Earned over 5 years is $81.58, with a median of $68.01 recorded in 2025.
  • Year-over-year, Times Interest Earned tumbled 64.8% in 2022 and then surged 314.92% in 2025.
  • Regeneron Pharmaceuticals' Times Interest Earned stood at $65.91 in 2022, then dropped by 19.34% to $53.16 in 2023, then soared by 77.38% to $94.3 in 2024, then dropped by 23.52% to $72.12 in 2025, then plummeted by 30.9% to $49.84 in 2026.
  • According to Business Quant data, Times Interest Earned over the past three periods came in at $49.84, $72.12, and $53.2 for Q1 2026, Q4 2025, and Q3 2025 respectively.